Kieser Group
Viral Signaling and Targeting Strategies
The viral signaling and targeting strategies group investigates the molecular basis of cell transformation by the latent membrane protein 1 (LMP1), the primary oncogene of the human Epstein-Barr tumor virus (EBV). Using state-of-the-art technologies such as proteomics, we focus at elucidating the molecular interactions of LMP1 with the cellular signaling network to define LMP1’s contribution to chronic disease development by EBV infection. The aim is to identify and validate novel targets and to develop targeting strategies such as small molecule inhibitors to interfere with LMP1 signaling and lymphomagenesis by EBV. The relevance of such new targets for other diseases are also investigated.
Group Leader Viral Signaling and Targeting Strategies
Postdoc Kieser Lab
Technical Assistant, Kieser Lab
Master Student Kieser Lab
Our Publications
Giehler, F. ; Ostertag, M.S. ; Sommermann, T. ; Weidl, D. ; Sterz, K. ; Kutz, H. ; Moosmann, A. ; Feller, S.M. ; Geerlof, A. ; Biesinger, B. ; Popowicz, G.M. ; Kirchmair, J. ; Kieser, A.
Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex.Voigt, S. ; Sterz, K. ; Giehler, F. ; Mohr, A.-W. ; Wilson, J.B. ; Moosmann, A. ; Kieser, A.
A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation.Contact
